4-Hydroxyisoleucine (4-HIL) Enriched Fenugreek Extract for Management of Polycystic Ovary Syndrome (PCOS)

• First-in-class phytopharmaceutical for Polycystic Ovary Syndrome (PCOS), addressing both metabolic (insulin resistance) and reproductive dysfunction (ovulation, follicular health).
• Synergistic multi-component composition (4-HIL, Trigonelline, Pinitol, Raffinose) offering superior efficacy compared to single-molecule or conventional therapies.
• Simple, scalable, and cost-effective production of 4-HIL enriched fraction and >95% pure 4-HIL without chromatography or ion-exchange resins.
• Preclinical data demonstrates improved ovulation rate, reduced cystic follicles, and enhanced ovarian health

• Novel phytopharmaceutical from Trigonella foenum-graecum enriched in 4-Hydroxyisoleucine (4-HIL), Trigonelline, Pinitol, and Raffinose for managing PCOS.
• Dual therapeutic benefit: improves insulin sensitivity and restores ovarian function.
• Scalable and cost-effective production process without complex purification steps.
• Offers a promising plant-based alternative to existing therapies for PCOS-related infertility and metabolic issues.

• Safe, plant-derived formulation with known dietary acceptability.
• Synergistic action of multiple components enhances therapeutic efficacy.
• Effective management of both metabolic and reproductive symptoms of PCOS.
• Cost-effective and industrially scalable production.
• Reduced side-effect potential compared to conventional synthetic drugs.